Loading...
Combination treatment with U0126 and rt-PA prevents adverse effects of the delayed rt-PA treatment after acute ischemic stroke
In acute ischemic stroke, the only FDA-approved drug; recombinant tissue plasminogen activator (rt-PA) is limited by restricted time-window due to an enhanced risk of hemorrhagic transformation which is thought to be caused by metalloproteinase (MMP). In experimental stroke inhibitors of the mitogen...
Saved in:
| Published in: | Sci Rep |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Nature Publishing Group UK
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8184783/ https://ncbi.nlm.nih.gov/pubmed/34099834 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-91469-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|